Desentum Raises M€8 in Funding
- Desentum, an Espoo, Finland-based biopharmaceutical company advancing an allergy vaccine candidate, raised 8 M€ in funding
- The round was arranged by Springvest Oyj
- The company intends to use the funds for funding further clinical development, R&D of new hypoallergens and business development
- The platform develops novel immunotherapeutic hypoallergens, so called allergy vaccines
- The hypoallergens are biotechnologically produced, modified allergen proteins aimed for improving the efficiency of allergen immunotherapy while also reducing the time required for treatment
- Founded in 2011, the company is a spin-off company from VTT Technical Research Centre of Finland Ltd
